Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and period: Specialty pharmaceutical developer focused on critical-care and other prescription products. This fiscal second-quarter report covers the three and six months ended March 31, 2020; the balance-sheet comparison is with September 30, 2019. The company had no operating revenue and was developing Mino-Lok, Mino-Wrap and Halo-Lido, and held an option to license a potential ARDS therapy.
Financial performance and condition
- Revenue: $0 for both the three- and six-month periods in 2020 and 2019. Gross margin is not meaningful without revenue.
- Quarter ended March 31: Operating expenses were $4.43 million, up from $3.64 million; operating loss was $4.43 million versus $3.64 million; net loss was $4.42 million versus $3.63 million. Basic and diluted loss per share was $0.13 versus $0.20.
- Six months ended March 31: Operating expenses were $8.88 million, up from $7.51 million; operating loss was $8.88 million versus $7.51 million; net loss was $8.75 million versus $7.51 million. Loss per share was $0.28 versus $0.41.
- Expenses: Six-month R&D increased 23% to $4.68 million, including $3.71 million for Mino-Lok and $0.88 million for Halo-Lido. G&A rose to $3.82 million from $3.33 million. The company attributed higher G&A in part to advisory, legal and investor-relations costs, including $406,020 of stock issued for services during the period.
- Cash flow and liquidity: Operating cash use was $9.58 million for the six months, compared with $6.01 million in 2019. Financing provided $6.03 million, primarily from warrant exercises. Cash fell to $4.34 million from $7.89 million at September 30, 2019. The balance sheet reports current assets of $4.39 million and current liabilities of $3.11 million.
- Debt and other obligations: Related-party notes payable were $172,970, with $82,268 of accrued related-party interest. Operating lease liabilities totaled $1.09 million. Total liabilities were $4.05 million.
- Capital structure: Common shares outstanding were 38.08 million at March 31, 2020, versus 28.93 million at September 30, 2019. The filing lists 23.50 million warrants outstanding at quarter-end.
Changes, outlook and risks
- Management reported substantial doubt about the company’s ability to continue as a going concern. It said available cash was expected to fund operations only into the third quarter of fiscal 2020, and planned to seek equity financing and other funding; success and timing were uncertain.
- Management expected R&D spending to increase as it pursued the Mino-Lok Phase 3 trial, advanced Halo-Lido and began Mino-Wrap development. The filing reported a positive outcome from Mino-Lok’s interim futility analysis and, at that time, expected topline data from the next interim analysis in the first half of 2020.
- The company disclosed that COVID-19 had disrupted hospitals and trial sites, slowed the estimated Mino-Lok trial completion timeline to September–December 2021, and could further affect enrollment, staffing, costs and regulatory interactions.
- Subsequent events: Nasdaq notified the company that its share price had fallen below the $1.00 minimum bid requirement; the compliance period was extended to December 14, 2020. The company received $164,583 in PPP funding in April. A May registered direct offering was announced for $7.5 million gross proceeds, with closing expected May 18, subject to customary conditions.
- Other unusual items: A $110,207 FDA fee refund was recorded as other income in the six-month period. The company adopted lease accounting effective October 1, 2019, recognizing a $1.14 million right-of-use asset and lease liability at adoption. It entered into an ARDS-therapy option agreement with a Novellus subsidiary; the chairman was a director and significant shareholder of Novellus, and the filing states the disinterested directors and Audit Committee approved the agreement.
Important facts to verify
- Working-capital inconsistency: The balance sheet implies positive working capital of $1,280,860, and the going-concern note also describes that amount as working capital. The MD&A instead calls it a working-capital deficit. Confirm the correct presentation.
- Confirm current cash runway and funding needs against the company’s disclosed cash-burn rate and the subsequent May offering; the filing’s runway statements refer to different periods (“into the third quarter” and “through June 2020”).
- Check subsequent disclosures for the outcome of the May offering, Nasdaq bid-price compliance, PPP loan treatment and Mino-Lok trial timing/results.
- Review dilution and potential future share issuance from outstanding warrants, options and the new equity incentive plan.